Hereditary Gastric Cancer Panel, Sequencing and Deletion/Duplication
Also known as: GASCAN NGS
Use
This test is designed to confirm a hereditary cause of gastric cancer in individuals with a personal or family history of the disease. Pathogenic germline variants in multiple genes are linked to hereditary gastric cancer, which is often characterized by early disease onset (typically before 50 years of age) and multiple, multifocal, or similar cancers in a single individual or in closely related family members. Approximately 5-10 percent of gastric cancers are associated with hereditary causes.
Special Instructions
Not provided.
Limitations
A negative result does not exclude a heritable form of gastric cancer or other cancers. This test only detects variants within the coding regions and intron-exon boundaries of the targeted genes. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Variants such as regulatory region variants and deep intronic variants will not be identified. The test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations, mitochondrial DNA variants, noncoding transcripts, complex structural rearrangements, or repeat expansions.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
2 mL
Container
Lavender or pink (EDTA) or yellow (ACD solution A or B). For New York State Clients: Lavender (K2EDTA or K3EDTA)
Storage Instructions
Refrigerated.
Causes for Rejection
Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue; DNA.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours; New York State Clients: 48 hours |
| Refrigerated | 1 week; New York State Clients: 2 weeks |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant